Rationale and Design of the DIGIT-HF Trial (DIGitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure): A Randomized, Double-Blind, Placebo-Controlled StudyUdo Bavendiek, Johann Bauersachs, Christopher Piorkowski et al.|European Journal of Heart Failure|2019Cited by 82
Digitoxin in Patients with Heart Failure and Reduced Ejection FractionUdo Bavendiek, Johann Bauersachs, Anika Großhennig et al.|New England Journal of Medicine|2025Cited by 65
Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trialUdo Bavendiek, Johann Bauersachs, Anika Großhennig et al.|Clinical Research in Cardiology|2023Cited by 18
LB01 SIX WEEKS OF SOFOSBUVIR/LEDIPASVIR TREATMENT OF ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: FINAL RESULTS OF THE THE GERMAN HEPNET ACUTE HCV IV STUDYKatja Deterding, Maurizio Degiuli, Christoph D. Spinner et al.|United European Gastroenterology Journal|2016Cited by 5